Special emphasis on bone health management in prostate cancer patients: a prospective longitudinal study
Conclusion: Bone-directed therapy (Zoledronic acid) leads to both subjective and objective improvement in bone health of prostate cancer patients on ADT.
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
More News: Back Pain | Cancer | Cancer & Oncology | Carcinoma | DEXA Scan | Orthopaedics | Osteoporosis | Pain | Pain Management | PET Scan | Prostate Cancer | Reclast | Study | Urology & Nephrology | Zometa